Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects

Digestive Diseases and Sciences

Volumn 56, Issue 7, 2011, Pages 2067-2072

  Pimentel, Mark ^a   Morales, Walter ^a   Chua, Kathleen ^a   Barlow, Gillian ^a   Weitsman, Stacy ^a   Kim, Gene ^a   Amichai, Meridythe M ^a   Pokkunuri, Venkata ^a   Rook, Emily ^a   Mathur, Ruchi ^a   Marsh, Zachary ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Antibiotics; IBS; Retreatment; Rifaximin

Indexed keywords

RIFAXIMIN;

ADULT; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETREATMENT; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; RETREATMENT; RETROSPECTIVE STUDIES; RIFAMYCINS; TREATMENT OUTCOME;

EID: 79959699085     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1728-5     Document Type: Article

References (15)

1. Bommelaer G, Poynard T, Le Pen C, et al. Prevalence of irritable bowel syndrome (IBS) and variability of diagnostic criteria. Gastroenterol Clin Biol. 2004;28:554-561. (Pubitemid 38917487)
2. El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health-related quality of life. Rev Gastroenterol Disord. 2003;3:S3-S11. (Pubitemid 36621502)
3. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology. 1995;109:671-680.
4. Pyleris E, Bourboulis EG, Koussoulas B, Barbatzas C. Prevalence of small intestinal bacterial overgrowth in a greek cohort: relationship with irritable bowel syndrome. Presented at the 18th United European gastroenterology week. Barcelona, Spain, 2010.
5. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: sub-analysis of a double-blind randomized controlled study. Dig Dis Sci. 2006;51:1297-1301. (Pubitemid 44315794)
6. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326-333. (Pubitemid 43381675)
7. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145:557-563. (Pubitemid 46780934)
8. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.
9. Gerard L, Garey KW, DuPont HL. Rifaximin: A nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Therapy. 2005;3:201-211. (Pubitemid 40590326)
10. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity - a review. Chemotherapy. 2005;51:67-72. (Pubitemid 40663191)
11. Debbia EA, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother. 2008;20:186-194. (Pubitemid 351797058)
12. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci. 2008;53:169-174. (Pubitemid 350265666)
13. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7:1279-1286.
14. Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55:2441-2449.
15. Posserud I, Stotzer PO, Bjornsson ES, Abrahamsson H, Simren M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802-808. (Pubitemid 46854194)